AEON - AEON Biopharma, Inc.

1.06
0.030   2.830%

Share volume: 39,043
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$1.03
0.03
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
45%
Profitability 53%
Dept financing 43%
Liquidity 34%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0.95%
3 Months
39.46%
6 Months
46.21%
1 Year
60.58%
2 Year
-91.32%
Key data
Stock price
$1.06
P/E Ratio 
N/A
DAY RANGE
$1.02 - $1.08
EPS 
$5.58
52 WEEK RANGE
$0.38 - $1.45
52 WEEK CHANGE
$15.22
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
11.838 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-26-2025
NEXT EARNINGS DATE
05-13-2025
BETA 
0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$58,230
AVERAGE 30 VOLUME 
$86,571
Company detail
CEO: Marc Forth
Region: US
Website: aeonbiopharma.com
Employees: 0
IPO year: 2021
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.

Recent news